Nevro Q2 2023 Earnings Report

Nevro EPS Results

• Actual EPS: -$0.69
• Consensus EPS: -$0.68
• Beat/Miss: Missed by -$0.01
• One Year Ago EPS: -$0.71

Nevro Revenue Results

• Actual Revenue: $108.80 million
• Expected Revenue: $108.19 million
• Beat/Miss: Beat by +$610.00 thousand
• YoY Revenue Growth: +4.40%

Nevro Announcement Details

• Quarter: Q2 2023
• Date: 8/1/2023
• Time: After Market Closes

Nevro (NYSE:NVRO), a medical device company, engages in the provision of products for patients suffering from chronic pain in the United States and internationally. The company provides HFX spinal cord stimulation (SCS) platform, which includes the Senza SCS implantable pulse generator (IPG) system, an evidence-based neuromodulation system for the treatment of chronic back and leg pain through paresthesia-free 10 kHz therapy, as well as offers Senza II and Senza Omnia SCS IPG systems. It also offers Senza HFX iQ platform, that includes HFX iQ implantable pulse generator, HFX trial stimulator, and HFX iQ patient remote, as well as HFX App, a patient remote control and the wireless trialing system; and provides sacroiliac joint fusion devices under NevroV1, NevroFix, and NevroPro brands. In addition, the company offers surpass surgical and percutaneous leads. It sells its products through its direct sales force, and a network of sales agents and independent distributors. The company was incorporated in 2006 and is headquartered in Redwood City, California.